Seattle Genetics is an industry leader in developing antibody-drug conjugates (ADCs). ADC is a technology designed to control the targeting capability of monoclonal antibodies. Through the technology, monoclonal antibodies inject cell-killing agents directly to cancer cells. The antibody-drug conjugates are meant to spare non-targeted cells hence eliminating most of the harmful effects of traditional chemotherapy. ADCs can also enhance antitumor activity. Engineered monoclonal antibodies have provided a therapeutic advantage to cancer patients as well as people with autoimmune diseases/ acute ailments.
The biotechnology company, Seattle Genetics is advancing its product pipeline to address major unmet medical needs. The company has produced the first new class of ADCs known as ADCETRIS® (brentuximab vedotin). Seattle Genetics is carrying out a huge clinical development program to evaluate the potential of ADCETRIS as a foundation in treating CD30-expressing lymphomas. The biotechnology company is also advancing an innovative ADC known as vadastuximab talirine (SGN-CD33A; 33A). The ADC is being analyzed in the Phase 3 CASCADE trial for severe myeloid leukemia (AML).
ADCETRIS and 33A are among the many ADCs in clinical advancement using Seattle Genetics’ proprietary technology. The company’s ADC technology is also used by associates who are developing several programs using Seattle Genetics’ proprietary tactic. The company is committed to enhancing treatment for patients through internal research and development as well as partnerships and scientific advancements.
Clay Siegall co-founded Seattle Genetics in 1997. He serves as the CEO, president and chairperson of the board of Seattle Genetics. Dr. Siegall is a scientist by profession and has built the company on a foundation of thorough research, scientific advancements, drug development practices and a passion for assisting patients. He has almost 20 years of experience in therapeutic drug development and cancer research. Clay Siegall holds a B.S. in Zoology from the University of Maryland and a PhD in Genetics from George Washington University.
Dr. Siegall has guided the firm to its current top position in creating antibody-drug conjugates for treating cancer and in attaining the approval for its first ADC product, ADCETRIS® (brentuximab vedotin) in 2011. He has also spearheaded the company’s capital raising initiatives, raising more than $330 million through private and public financing. Clay Siegall has made strategic partnerships such as the exclusive global collaboration agreement with Genentech for SGN-40.